Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Adverse events reported highlight the safety profile of zilovertamab vedotin in clinical settings.
• Outcomes include various types of adverse events across the participant group during the study period.
• The study utilizes a phase 2 approach to assess the efficacy and safety of the treatment for metastatic conditions.
• Significant findings may influence future research directions and clinical practices in oncology.